Getting to Know RAD 1901
If you’re looking to stay up to date on the latest in the world of selective androgen receptor modulators (SARMs) and related substances these days to take your bodybuilding gains up a notch, then you should definitely keep an eye on RAD 1901.
The Lowdown on RAD 1901
RAD 1901 is basically a type of tissue-selective estrogen receptor degrader or SERD that is designed to help treat metastatic breast cancer and breast cancer brain metastases (BCBM) in postmenopausal women.
Moreover, RAD 1901 is also formulated as a selective estrogen receptor modulator (SERM) to relieve the vasomotor symptoms of these diseases in individuals suffering from the same and even prevent potential relapses, including the onset of bone loss and uterine endometrium stimulation.
This combined SERD and SERM is still currently going through extensive clinical trials and being administered to postmenopausal women who have advanced breast cancer for evaluation of its overall effects.
A Quick Look at How RAD 1901 Works
At its simplest, RAD 1901 binds to the estrogen receptors or ER’s as soon as it is absorbed by the body as seen in ovariectomy-induced osteopenia rat models.
Besides significantly disrupting their activity to hold the production and release of excess estrogen hormones that are considered as the primary catalysts of metastatic breast cancer, this SERM and SERD all rolled into one also degrades ER’s that blocked the proliferation of estrogen via basal and estradiol channels in the process.
These actions not only deter the possibility of a relapse of the disease in the long run, but prevent the cancer from becoming impervious to drug interference due to acquired or de novo endocrine resistance, which are effects that traditional aromatase inhibitors can’t instigate.
Additionally, subsequent tests show that it did not trigger uterine endometrium stimulation during administration and even appeared to provide protection against bone loss.
Who is Behind the Development of RAD 1901?
RAD 1901 is the brainchild of Radius, a biopharmaceutical company that develops therapeutic medical products aimed at easing and healing osteoporosis as well as endocrine-mediated illnesses like hormone-resistant/hormone-driven breast cancer.
We will keep you posted with more information about RAD 1901 as soon as we get hold of new developments on this combined SERD and SERM that will potentially revolutionize breast cancer treatment.
Click here to learn more about SARMS and their key benefits.